HU9602712D0 - Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them - Google Patents

Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them

Info

Publication number
HU9602712D0
HU9602712D0 HU9602712A HU9602712A HU9602712D0 HU 9602712 D0 HU9602712 D0 HU 9602712D0 HU 9602712 A HU9602712 A HU 9602712A HU 9602712 A HU9602712 A HU 9602712A HU 9602712 D0 HU9602712 D0 HU 9602712D0
Authority
HU
Hungary
Prior art keywords
xanthine
reactivity
producing
reducing
novel
Prior art date
Application number
HU9602712A
Other languages
Hungarian (hu)
Other versions
HUT74732A (en
Inventor
Hiristo Anagnostopulos
Ulrich Gebert
Alexander Kapp
Claus Kroegel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of HU9602712D0 publication Critical patent/HU9602712D0/en
Publication of HUT74732A publication Critical patent/HUT74732A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU9602712A 1994-04-05 1995-03-21 Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them HUT74732A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4411660A DE4411660A1 (en) 1994-04-05 1994-04-05 Use of xanthine derivatives to reduce the pathological hyperreactivity of eosinophilic granulocytes, new xanthine compounds and processes for their preparation

Publications (2)

Publication Number Publication Date
HU9602712D0 true HU9602712D0 (en) 1996-11-28
HUT74732A HUT74732A (en) 1997-02-28

Family

ID=6514636

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9602712A HUT74732A (en) 1994-04-05 1995-03-21 Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them

Country Status (11)

Country Link
EP (1) EP0758239A1 (en)
JP (1) JPH09510983A (en)
KR (1) KR100373948B1 (en)
CN (1) CN1098686C (en)
AU (1) AU695488B2 (en)
CA (1) CA2187081A1 (en)
DE (1) DE4411660A1 (en)
HU (1) HUT74732A (en)
RU (1) RU2159617C2 (en)
UA (1) UA39136C2 (en)
WO (1) WO1995026727A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
AU3370099A (en) * 1998-03-31 1999-10-18 Mayo Foundation For Medical Education And Research Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
CN101538224A (en) * 2002-05-31 2009-09-23 先灵公司 Process for preparing xanthine phosphodiesterase V inhibitors and precursers thereof
SI1509525T1 (en) * 2002-05-31 2006-12-31 Schering Corp Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918297D0 (en) * 1989-08-10 1989-09-20 Beecham Group Plc Novel treatment
DD298051A5 (en) * 1989-08-16 1992-02-06 ��@���������@�������k�� PROCESS FOR THE PREPARATION OF A THERAPEUTIC AGENT FOR THE TREATMENT OF DIGESTIVE DISEASES
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
WO1993003728A1 (en) * 1991-08-27 1993-03-04 Temple University Of The Commonwealth System Of Xanthine suppression of antigen activation of t- or b-cells
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Compositions for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds

Also Published As

Publication number Publication date
EP0758239A1 (en) 1997-02-19
UA39136C2 (en) 2001-06-15
RU2159617C2 (en) 2000-11-27
KR970702044A (en) 1997-05-13
AU1951095A (en) 1995-10-23
WO1995026727A1 (en) 1995-10-12
KR100373948B1 (en) 2003-06-09
DE4411660A1 (en) 1995-10-12
AU695488B2 (en) 1998-08-13
CN1145029A (en) 1997-03-12
CN1098686C (en) 2003-01-15
CA2187081A1 (en) 1995-10-12
HUT74732A (en) 1997-02-28
JPH09510983A (en) 1997-11-04

Similar Documents

Publication Publication Date Title
ZA847963B (en) Process for titanium alloys
EP0699695A3 (en) Process for the preparation of copolyacetals
ZA954324B (en) Process for the preparation of 3-aryluracils
GB9504711D0 (en) Process for the preparation of chloropyrimidines
AU7660091A (en) Catalytic hydroisomerization process
GB2246345B (en) Process for the recovery of titanium values
AU4311696A (en) Process for the preparation of lamotrigine
AU6183790A (en) Process for reducing the swellability of starches
GB9509826D0 (en) Process for the preparation of imidazolutidine
HU9602712D0 (en) Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them
DE3569106D1 (en) Process for the preparation of 6-chloro-2,4-nitroaniline
EP0441166A3 (en) Process for the preparation of finished, thermomigrating dyeings
GB2295981B (en) Method of manufacturing structural parts, particularly for use in aircraft
EP0682034A3 (en) Process for organooxylation of cyanoalkylchlorosilanes.
IL85836A0 (en) Process for the synthesis of alpha-(1-methylethyl)-3,4-dimethoxybenzene-acetonitrile
PL320799A1 (en) 14alpha, 17alpha-c2-bridged derivatives of 19-norprogesterone
ZA9510318B (en) New process for the preparation of sameridine
ZA9510894B (en) Process for the preparation of chloromethylpyridines
EP0712857A3 (en) Process for the preparation of alkylglycosides
ZA959322B (en) Process for the preparation of 1-halo-3-trialkylsilanyl-benzene derivatives
EP0690056A3 (en) Process for the preparation of purins
GB2164946B (en) New restriction enzyme and process for producing the same
ZA876874B (en) Cereal milling process
IL113555A0 (en) Process for the synthesis of haloalkylferrocenes
EP0701984A3 (en) Process for the preparation of alkaliamides